Skip to main content

Mito-LND (C09-1152-413)

Aladdin

Catalog No.
C09-1152-413
Manufacturer No.
M647144-25mg
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $1,321.08
List Price: $1,467.87

Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species , and induces autophagic

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species , and induces autophagic cell death in lung cancer cells.In VitroMito-LND blocks lung cancer growth, migration, and invasion. Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC 50 values of 0.74 µM and 0.69 µM, respectively. Mito-LND inhibits mitochondrial complex I and II activities with IC 50 values of 1.2 µM and 2.4 µM, respectively in H2030BrM3 cells. Mito-LND (1 µM) increases ROS generation in H2030BrM3 lung cancer cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells. Mito-LND (2 µM) decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoMito-LND (7.5 µmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) treatment markedly enhanced potency against both lung cancer progression and metastasis . Mito-LND also decreases the rate of growth of A549 tumor xenografts . Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Athymic nude mice (5 weeks) injected with H2030BrM3 cells Dosage: 7.5 µmol/kg Administration: Oral gavage; 5 days per week; for 3 consecutive weeks Result: Significantly decreased tumor progression.Form:Solid. Specification: 0.97 Molecular Formula: C43H45BrCl2N3OP Molecular Weight: 801.62 PubChem CID: 155977659 Isomeric SMILES: C1=CC=C(C=C1)[P+](CCCCCCCCCCNC(=O)C2=NN(C3=CC=CC=C32)CC4=C(C=C(C=C4)Cl)Cl)(C5=CC=CC=C5)C6=CC=CC=C6.[Br-]
UPC:
12352005
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
M647144-25mg
CAS:
2361564-49-8
Product Size:
25mg


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.